INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 421m ago
HOUSE PTR20m ago
SEC 13F20m ago
ROBINHOOD CHAIN20m ago
IK
Corporate insider

Issa Mohamed Khairie

EVP, Head of US OncologyCIK 0002050035

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 1
Max Insider Score18
Connections with evidence1

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
11
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Grant or award
A—
14.2K sh
Jan 16, 2026Jan 21, 2026
traded Jan 16, 2026
+5dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    INCYTE CORPEVP, Head of US Oncology · Jan 8, 2026
9
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Tax withholding · 10b5-1 plan
F
$881K
8,264 sh
Jan 6, 2026
Jan 8, 2026
traded Jan 6, 2026
+2d
SEC FORM 4

Evidence

18
IK
Issa Mohamed KhairieEVP, Head of US Oncology
INCYINCYTE CORP
Open-market sale · 10b5-1 plan
SELL$1.18M
10.9K sh
Jan 7, 2026Jan 8, 2026
traded Jan 7, 2026
+1dSEC FORM 4

Evidence